180 Poster - Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors.

MLA

Papadopoulos, K., et al. “180 Poster - Early Evidence of Dose-Dependent Pharmacodynamic Activity Following Treatment with SY-5609, a Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Advanced Solid Tumors.” European Journal of Cancer, vol. 138, Oct. 2020, p. S50. EBSCOhost, https://doi.org/10.1016/S0959-8049(20)31211-9.

APA

Papadopoulos, K., Sharma, M., Hamilton, E., Richardson, D., Bashir, B., Hodgson, G., Ke, N., Kang-Fortner, Q., Zhou, L., Zamboni, W., Jolin, H., Madigan, C., Kelly, M., & Roth, D. (2020). 180 Poster - Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors. European Journal of Cancer, 138, S50. https://doi.org/10.1016/S0959-8049(20)31211-9

Chicago

Papadopoulos, K., M. Sharma, E. Hamilton, D. Richardson, B. Bashir, G. Hodgson, N. Ke, et al. 2020. “180 Poster - Early Evidence of Dose-Dependent Pharmacodynamic Activity Following Treatment with SY-5609, a Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Advanced Solid Tumors.” European Journal of Cancer 138 (October): S50. doi:10.1016/S0959-8049(20)31211-9.